

Special Issue

Coronavirus: Vaccines and Other Therapeutics

Message from the Guest Editor

As is well known to the community, the major focus of our journal, *Vaccines* (ISSN 2076-393X) is on laboratory and clinical vaccine research, utilization, and immunization. The Special Issue on “Coronavirus Vaccines and Other Therapeutics” focuses on high-quality research in any basic and/or applied area related to the ongoing coronavirus pandemic. We welcome articles (high-quality reviews, regular research papers, communications, and case reports) contributing either fundamentally or clinically to the concerted effort worldwide to combat the ongoing coronavirus pandemic. In addition to works on the standard vaccination approach, we are also encouraging studies on other therapeutic endeavors, e.g., other modes of immunization, antigen arrest, as well as novel inhibitors. We are also interested in computational approaches, especially those based on direct experimental data, and would appreciate works combining computation and experiments.

Guest Editor

Dr. Sankar Basu

Asutosh College (Under Calcutta University, Kolkata, India), Department of Microbiology & External Scientific Collaborator at the 3BIO group, ULB, Brussels, Belgium

Deadline for manuscript submissions

closed (30 November 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



mdpi.com/si/85423

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 5.2
CiteScore 8.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).